PURPOSE: It is well known that methylation plays an important role in regulating tissue expression of proopiomelanocortin (POMC) and recent studies have shown that demethylation can occur also in vitro in neuroendocrine tumors. Aim of the present study was to evaluate whether inhibition of methylation modulates POMC expression and ACTH secretion by human corticotrope tumors. METHODS: Twenty two ACTH-secreting pituitary tumors were incubated with 5-AZA-2'-deoxycytidine (AZA), an inhibitor of DNA-methyltransferases, with or without 10 nM corticotropin-releasing hormone (CRH). Both dose response (100 nM-10 μM AZA) and time course (4-96 h) experiments were carried out for measurement of ACTH secretion and POMC gene expression. RESULTS: Incubation with AZA increased constitutive POMC expression and ACTH secretion by human corticotrope adenomas. The effect appeared most notable at 24 and 48 h with 1 μM AZA. Incubation with AZA did not exert an additional stimulatory effect on CRH-stimulated POMC and ACTH. CONCLUSIONS: The present study shows that AZA increases POMC gene expression and ACTH secretion in human pituitary ACTH-secreting tumors. This can be taken to indicate that mechanisms set into motion by AZA play a role in the regulation of ACTH secretion/POMC expression in tumoral corticotropes and paves the way to further studies in Cushing's disease.
PURPOSE: It is well known that methylation plays an important role in regulating tissue expression of proopiomelanocortin (POMC) and recent studies have shown that demethylation can occur also in vitro in neuroendocrine tumors. Aim of the present study was to evaluate whether inhibition of methylation modulates POMC expression and ACTH secretion by human corticotrope tumors. METHODS: Twenty two ACTH-secreting pituitary tumors were incubated with 5-AZA-2'-deoxycytidine (AZA), an inhibitor of DNA-methyltransferases, with or without 10 nM corticotropin-releasing hormone (CRH). Both dose response (100 nM-10 μM AZA) and time course (4-96 h) experiments were carried out for measurement of ACTH secretion and POMC gene expression. RESULTS: Incubation with AZA increased constitutive POMC expression and ACTH secretion by human corticotrope adenomas. The effect appeared most notable at 24 and 48 h with 1 μM AZA. Incubation with AZA did not exert an additional stimulatory effect on CRH-stimulated POMC and ACTH. CONCLUSIONS: The present study shows that AZA increases POMC gene expression and ACTH secretion in human pituitary ACTH-secreting tumors. This can be taken to indicate that mechanisms set into motion by AZA play a role in the regulation of ACTH secretion/POMC expression in tumoral corticotropes and paves the way to further studies in Cushing's disease.
Authors: Rosario Pivonello; Diego Ferone; Wouter W de Herder; Johan M Kros; Maria Laura Del Basso De Caro; Marica Arvigo; Lucio Annunziato; Gaetano Lombardi; Annamaria Colao; Leo J Hofland; Steven W J Lamberts Journal: J Clin Endocrinol Metab Date: 2004-05 Impact factor: 5.958
Authors: Leo J Hofland; Joost van der Hoek; Richard Feelders; Maarten O van Aken; Peter M van Koetsveld; Marlijn Waaijers; Diana Sprij-Mooij; Christian Bruns; Gisbert Weckbecker; Wouter W de Herder; Albert Beckers; Steven W J Lamberts Journal: Eur J Endocrinol Date: 2005-04 Impact factor: 6.664
Authors: Stefan Ehrlich; Deike Weiss; Roland Burghardt; Carmen Infante-Duarte; Simone Brockhaus; Marc A Muschler; Stefan Bleich; Ulrike Lehmkuhl; Helge Frieling Journal: J Psychiatr Res Date: 2010-02-21 Impact factor: 4.791
Authors: F Pecori Giraldi; S Pesce; P Maroni; L Pagliardini; G Lasio; M Losa; F Cavagnini Journal: J Neuroendocrinol Date: 2010-01-27 Impact factor: 3.627
Authors: Antonella Sesta; Maria Francesca Cassarino; Mariarosa Terreni; Alberto G Ambrogio; Laura Libera; Donatella Bardelli; Giovanni Lasio; Marco Losa; Francesca Pecori Giraldi Journal: Neuroendocrinology Date: 2019-10-16 Impact factor: 4.914